Repeated Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Selected Patients Affected by Peritoneal Metastases: Italian PSM Oncoteam Evidence
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Design, Setting, and Patients
2.2. Data Collection
2.3. Cytoreductive Surgery
2.4. HIPEC
2.5. Definitions
2.6. Data Analysis
3. Results
3.1. Population Characteristics
3.2. Procedure Characteristics and Complications
3.3. Peritoneal Cancer Index, Completeness of Cytoreduction and Procedure Safety
3.4. Three or More Iterative Procedures
3.5. Overall Survival
4. Discussion
4.1. Key Results
4.2. Interpretation and Comparison with The Literature
4.3. Strengths and Weaknesses
4.4. Relevance of The Findings, and Unanswered Questions
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Colbourne, J.R.M.; Alhayo, S.T.; Nandakumar, B.; Barat, S.; Liauwi, W.; Morris, D.L.; Alzahrani, N.A. Cost-effectiveness of Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis. Vivo 2022, 36, 1527–1533. [Google Scholar] [CrossRef]
- Votanopoulos, K.I.; Ihemelandu, C.; Shen, P.; Stewart, J.H.; Russell, G.B.; Levine, E.A. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J. Am. Coll. Surg. 2012, 215, 412–417. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sugarbaker, P.H. Cytoreductive surgery and perioperative intraperitoneal chemotherapy: A new standard of care for appendiceal mucinous tumors with peritoneal dissemination. Clin. Colon Rectal Surg. 2005, 18, 204–214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bekhor, E.; Carr, J.; Hofstedt, M.; Sullivan, B.; Solomon, D.; Leigh, N.; Bolton, N.; Golas, B.; Sarpel, M.U.; Labow, D.; et al. The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis. Ann. Surg. Oncol. 2020, 27, 1448–1455. [Google Scholar] [CrossRef] [PubMed]
- Choudry, H.A.; Bednar, F.; Shuai, Y.; Jones, H.L.; Pai, R.K.; Pingpank, J.F.; Ahrendt, S.S.; Holtzman, M.P.; Zeh, H.J.; Bartlett, D.L. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases. Ann. Surg. Oncol. 2019, 26, 1445–1453. [Google Scholar] [CrossRef]
- Lopez-Ramirez, F.; Gushchin, V.; Sittig, M.; King, M.C.; Baron, E.; Nikiforchin, A.; Nieroda, C.; Sardi, A. Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix. Ann. Surg. Oncol. 2022, 29, 3390–3401. [Google Scholar] [CrossRef]
- Chua, T.C.; Moran, B.J.; Sugarbaker, P.H.; Levine, E.A.; Glehen, O.; Gilly, F.N.; Baratti, D.; Deraco, M.; Elias, D.; Sardi, A.; et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J. Clin. Oncol. 2012, 30, 2449–2456. [Google Scholar] [CrossRef] [Green Version]
- Sugarbaker, P.H. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006, 7, 69–76. [Google Scholar] [CrossRef]
- Yan, T.D.; Welch, L.; Black, D.; Sugarbaker, P.H. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann. Oncol. 2007, 18, 827–834. [Google Scholar] [CrossRef]
- Elias, D.; Gilly, F.; Boutitie, F.; Quenet, F.; Bereder, J.M.; Mansvelt, B.; Lorimier, G.; Dube, P.; Glehen, O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J. Clin. Oncol. 2010, 28, 63–68. [Google Scholar] [CrossRef]
- Ji, Z.H.; Peng, K.W.; Yu, Y.; Li, X.B.; Yonemura, Y.; Liu, Y.; Sugarbaker, P.H.; Li, Y. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. Int. J. Hyperth. 2017, 33, 562–570. [Google Scholar] [CrossRef] [Green Version]
- Robella, M.; Vaira, M.; Marsanic, P.; Mellano, A.; Borsano, A.; Cinquegrana, A.; Sottile, A.; De Simone, M. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Minerva Chir. 2014, 69, 27–35. [Google Scholar]
- Glehen, O.; Gilly, F.N.; Boutitie, F.; Bereder, J.M.; Quenet, F.; Sideris, L.; Mansvelt, B.; Lorimier, G.; Msika, S.; Elias, D. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients. Cancer 2010, 116, 5608–5618. [Google Scholar] [CrossRef]
- Königsrainer, I.; Beckert, S.; Becker, S.; Zieker, D.; Fehm, T.; Grischke, E.M.; Lauk, O.; Glatzle, J.; Brücher, B.; Wallwiener, D. Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: Experience and lessons learned. Langenbecks Arch. Surg. 2011, 396, 1077–1081. [Google Scholar] [CrossRef]
- Marocco, F.; Vaira, M.; Milani, A.; Genta, S.; Maggiorotto, F.; Magistris, A.; Cinquegrana, A.; Robella, M.; De Simone, M.; Aglietta, M.; et al. Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer. Eur. J. Gynaecol. Oncol. 2016, 37, 638–643. [Google Scholar]
- Gill, R.S.; Al-Adra, D.P.; Nagendran, J.; Campbell, S.; Shi, X.; Haase, E.; Schiller, D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality, and morbidity. J. Surg. Oncol. 2011, 104, 692–698. [Google Scholar] [CrossRef]
- Yan, T.D.; Black, D.; Savady, R.; Sugarbaker, P.H. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J. Clin. Oncol. 2006, 24, 4011–4019. [Google Scholar] [CrossRef]
- Golse, N.; Bakrin, N.; Passot, G.; Mohamed, F.; Vaudoyer, D.; Gilly, F.N.; Glehen, O.; Cotte, E. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: Postoperative and long-term results. J. Surg. Oncol. 2012, 106, 197–203. [Google Scholar] [CrossRef]
- Brouquet, A.; Goéré, D.; Lefèvre, J.H.; Bonnet, S.; Dumont, F.; Raynard, B.; Elias, D. The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: Postoperative course and long-term outcome. Ann. Surg. Oncol. 2009, 16, 2744–2751. [Google Scholar] [CrossRef]
- Kianmanesh, R.; Scaringi, S.; Sabate, J.M.; Castel, B.; Pons-Kerjean, N.; Coffin, B.; Hay, J.-M.; Flamant, Y.; Msika, S. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann. Surg. 2007, 245, 597–603. [Google Scholar] [CrossRef]
- Verwaal, V.J.; Boot, H.; Aleman, B.M.P.; van Tinteren, H.; Zoetmulder, F.A.N. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: Location, treatment, and outcome. Ann. Surg. Oncol. 2004, 11, 375–379. [Google Scholar] [CrossRef]
- Oken, M.M.; Creech, R.H.; Tormey, D.C.; Horton, J.; Davis, T.E.; McFadden, E.T.; Carbone, P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982, 5, 649–655. [Google Scholar] [CrossRef]
- Dripps, R.D.; Lamont, A.; Eckenhoff, J.E. The role of anesthesia in surgical mortality. JAMA 1961, 178, 261–266. [Google Scholar] [CrossRef]
- Dindo, D.; Demartines, N.; Clavien, P.A. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 2004, 240, 205–213. [Google Scholar] [CrossRef]
- Sugarbaker, P.H. Peritonectomy procedures. Ann. Surg. 1995, 221, 29–42. [Google Scholar] [CrossRef]
- Jacquet, P.; Sugarbaker, P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat. Res. 1996, 82, 359–374. [Google Scholar]
- Brierley, J.; Gospodarowicz, M.K.; Wittekind, C. (Eds.) TNM Classification of Malignant Tumours, 8th ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2017. [Google Scholar]
- Tentes, A.A.K.; Tripsiannis, G.; Markakidis, S.K.; Karanikiotis, C.N.; Tzegas, G.; Georgiadis, G.; Avgidou, K. Peritoneal cancer index: A prognostic indicator of survival in advanced ovarian cancer. Eur. J. Surg. Oncol. 2003, 29, 69–73. [Google Scholar] [CrossRef]
- Kyang, L.S.; Alzahrani, N.A.; Valle, S.J.; Rahman, M.K.; Arrowaili, A.; Liauw, W.; Morris, D.L. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases. J. Surg. Oncol. 2019, 120, 794–802. [Google Scholar] [CrossRef]
- Yan, T.D.; Deraco, M.; Baratti, D.; Kusamura, S.; Elias, D.; Glehen, O.; Gilly, F.N.; Levine, E.A.; Shen, P.; Mohamed, F.; et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience. J. Clin. Oncol. 2009, 27, 6237–6242. [Google Scholar] [CrossRef]
- Bijelic, L.; Yan, T.D.; Sugarbaker, P.H. Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J. Surg. Oncol. 2008, 98, 295–299. [Google Scholar] [CrossRef]
- Esquivel, J.; Sugarbaker, P.H. Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: Analysis of prognostic factors in 98 patients. Ann. Surg. 2001, 234, 198–205. [Google Scholar] [CrossRef]
- Di Giorgio, A.; Naticchioni, E.; Biacchi, D.; Sibio, S.; Accarpio, F.; Rocco, M.; Tarquini, S.; Di Seri, M.; Ciardi, A.; Montruccoli, D.; et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008, 113, 315–325. [Google Scholar] [CrossRef]
- Sadeghi, B.; Arvieux, C.; Glehen, O.; Beaujard, A.C.; Rivoire, M.; Baulieux, J.; Gilly, F.N. Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000, 88, 358–363. [Google Scholar] [CrossRef]
- Saxena, A.; Yan, T.D.; Morris, D.L. Critical assessment of preoperative and operative risk factors for complications after iterative peritonectomy procedures. Eur. J. Surg. Oncol. 2010, 36, 309–314. [Google Scholar] [CrossRef]
- Yan, T.D.; Bijelic, L.; Sugarbaker, P.H. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann. Surg. Oncol. 2007, 14, 2289–2299. [Google Scholar] [CrossRef]
- Sommariva, A.; Tonello, M.; Cona, C.; Pilati, P.; Rossi, C.R. Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Peritoneal Metastases. Anticancer. Res. 2018, 38, 5521–5524. [Google Scholar] [CrossRef]
- Vaira, M.; Robella, M.; Mellano, A.; Sottile, A.; De Simone, M. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence. Int. J. Hyperth. 2014, 30, 565–569. [Google Scholar] [CrossRef]
- Pasqual, E.; Bertozzi, S.; Bacchetti, S.; Londero, A.P. Effektive Therapie bei peritonealen Neoplasmen mit niedrigem Peritoneal Cancer Index: Die Schwierigkeit der Diagnosesicherung. Interdiszip. Onkol. 2012, 4, 26–29. [Google Scholar]
- Pasqual, E.M.; Bertozzi, S.; Bacchetti, S.; Londero, A.P.; Basso, S.M.M.; Santeufemia, D.A.; Re, G.L.; Lumachi, F. Preoperative assessment of peritoneal carcinomatosis in patients undergoing hyperthermic intraperitoneal chemotherapy following cytoreductive surgery. Anticancer. Res. 2014, 34, 2363–2368. [Google Scholar]
- Noiret, B.; Piessen, G.; Eveno, C. Update of randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: A systematic review. Pleura Peritoneum 2022, 7, 51–61. [Google Scholar] [CrossRef]
Variable | Value |
---|---|
Age at diagnosis (years) | 51.65 (±11.44) |
BMI (kg/m2) | 25.12 (±4.25) |
Interval between diagnosis and first HIPEC (months) | 6 (2–11) |
Time interval between first and second intervention (months) | 19 (14–29) |
ASA physical Status | 2 (2–2) |
Center | |
IDC IRCCS (Torino) | 40% (26/65) |
IOV IRCCS (Padova) | 32.31% (21/65) |
ASUFC (Udine) | 21.54% (14/65) |
AOU G. Martino (Messina) | 6.15% (4/65) |
Primary Tumor | |
PMP | 50.77% (33/65) |
CRC | 23.08% (15/65) |
EOC | 15.38% (10/65) |
DMPM | 6.15% (4/65) |
GC | 3.08% (2/65) |
Sarcoma | 1.54% (1/65) |
Variable | First CRS and HIPEC (65) | Second CRS and HIPEC (65) | p |
---|---|---|---|
Patient characteristics | |||
ASA | 2.00 (2.00–2.50) | 2.00 (2.00–3.00) | 0.065 |
Intraoperative PCI | 15.00 (11.00–27.50) | 13.00 (6.00–18.50) | <0.05 |
Completeness of cytoreduction | |||
CC−0 | 73.85% (48/65) | 66.15% (43/65) | 0.444 |
CC−1 | 24.62% (16/65) | 24.62% (16/65) | 1.000 |
CC−2 | 0.00% (0/65) | 6.15% (4/65) | 0.119 |
CC−3 | 1.54% (1/65) | 3.08% (2/65) | 1.000 |
Blood transfusion | 67.69% (44/65) | 61.54% (40/65) | 0.463 |
Parenteral nutrition | 89.23% (58/65) | 86.15% (56/65) | 0.593 |
Reintervention | 13.85% (9/65) | 7.69% (5/65) | 0.258 |
Surgical complications (Clavien–Dindo classification) | |||
III–IV | 20.00% (13/65) | 10.77% (7/65) | 0.145 |
Operation duration (minutes) | 570.00 (405.00–710.00) | 480.00 (360.00–600.00) | <0.05 |
Hospitalization (days) | 17.00 (11.00–21.00) | 12.00 (8.00–17.00) | <0.05 |
Variable | Value |
---|---|
Patients | 9 |
ASA | 2 (2–2) |
Cytoreduction PCI | 8.75 (±5.75) |
Completeness of cytoreduction | |
CC−0 | 87.5% (7/8) |
CC−1 | 12.5% (1/8) |
Blood transfusion | 44.44% (4/9) |
Parenteral nutrition | 100% (9/9) |
Reintervention | 11.11% (1/9) |
Surgical complications (Clavien–Dindo classification) | |
III-IV | 11.11% (1/9) |
Operation duration (minutes) | 450 (310–495) |
Hospitalization (days) | 13 (9–15) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pasqual, E.M.; Londero, A.P.; Robella, M.; Tonello, M.; Sommariva, A.; De Simone, M.; Bacchetti, S.; Baiocchi, G.; Asero, S.; Coccolini, F.; et al. Repeated Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Selected Patients Affected by Peritoneal Metastases: Italian PSM Oncoteam Evidence. Cancers 2023, 15, 607. https://doi.org/10.3390/cancers15030607
Pasqual EM, Londero AP, Robella M, Tonello M, Sommariva A, De Simone M, Bacchetti S, Baiocchi G, Asero S, Coccolini F, et al. Repeated Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Selected Patients Affected by Peritoneal Metastases: Italian PSM Oncoteam Evidence. Cancers. 2023; 15(3):607. https://doi.org/10.3390/cancers15030607
Chicago/Turabian StylePasqual, Enrico Maria, Ambrogio P. Londero, Manuela Robella, Marco Tonello, Antonio Sommariva, Michele De Simone, Stefano Bacchetti, Gianluca Baiocchi, Salvatore Asero, Federico Coccolini, and et al. 2023. "Repeated Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Selected Patients Affected by Peritoneal Metastases: Italian PSM Oncoteam Evidence" Cancers 15, no. 3: 607. https://doi.org/10.3390/cancers15030607